BCM
RPRX

Bourgeon Capital Management’s Repros Therapeutics Inc. RPRX Stock Holding History

Bourgeon Capital Management’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-13,000
Closed -$231K – 128
2014
Q1 		$231K Buy
+13,000
New +$252K 0.15% 88

Other funds holding RPRX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Bourgeon Capital Management's RPRX Position: Q2 2014 in Review

Bourgeon Capital Management sold out of Repros Therapeutics Inc. (RPRX) in Q2 2014, closing a stake of 13,000 shares — an estimated $231K sold.

Bourgeon Capital Management first reported a position in RPRX in Q1 2014 and held it in 1 quarter. The position peaked at $231K in Q1 2014. 77 funds tracked by Wall St. Rank hold RPRX as of Q2 2014.

  • Bourgeon Capital Management reported no remaining Repros Therapeutics Inc. position as of Q2 2014 after selling out during the quarter.
  • Bourgeon Capital Management sold 13,000 Repros Therapeutics Inc. shares in Q2 2014, an estimated $231K.
  • Bourgeon Capital Management first reported a position in Repros Therapeutics Inc. in Q1 2014 and held it in 1 quarter.
  • Bourgeon Capital Management's Repros Therapeutics Inc. position peaked at $231K in Q1 2014.
  • 77 funds tracked by Wall St. Rank held Repros Therapeutics Inc. as of Q2 2014.

Based on Bourgeon Capital Management's 13F filing for Q2 2014, filed 1 Aug 2014.